UniQure rises as it seeks equity raise following FDA about-face

Stifel Financial

23/06/2026 15:59

** U.S.-listed shares of uniQure NV QURE.O up 7.6% to $47.76 on Tues as Dutch drugmaker looks to raise equity on heels of U.S. FDA reversing its earlier position on co's Huntington's disease treatment
** QURE late Mon kicked off $150 mln offering of stock and pre-funded warrants
** Last Weds, co's shares surged ~78% to close at $48.16 after U.S. health regulator said it will accept existing trial data for an accelerated review of AMT-130
** QURE intends to use net proceeds from offering to fund commercialization activities, potential commercial launches and studies of AMT-130,  and to develop other product candidates, among other purposes, per the prospectus 
** Leerink Partners and Stifel joint bookrunners
** Co has ~63.1 mln shares outstanding
** With the advance, U.S.-listed shares have doubled YTD
** 13 of 15 analysts rate the shares "strong buy" or "buy", 2 "hold"; median PT $60.50, per LSEG

(Lance Tupper is a Reuters market analyst. The views expressed are his own)
((lance.tupper@tr.com 1-646-279-6380))